Rishi Puri Mbbs

List of Publications by Year in Descending Order

159 papers	4,347 citations	35 h-index	62 g-index
182 ext. papers	5,842 ext. citations	5 avg, IF	5.68 L-index

#	Paper	IF	Citations
159	Surgical versus medical management of infective endocarditis after TAVR.. *Catheterization and Cardiovascular Interventions*, **2022**,	2.7	1
158	Right Ventricular-Pulmonary Arterial Coupling and Afterload Reserve in Patients Undergoing Transcatheter Tricuspid Valve Repair.. *Journal of the American College of Cardiology*, **2022**, 79, 448-461	15.1	0
157	HbA1c, Coronary atheroma progression and cardiovascular outcomes.. *American Journal of Preventive Cardiology*, **2022**, 9, 100317	1.9	0
156	Impact of Timing of Infective Endocarditis After Transcatheter Aortic Valve Implantation on Mortality.. *American Journal of Cardiology*, **2022**,	3	
155	Plaque microstructures during metformin therapy in type 2 diabetic subjects with coronary artery disease: optical coherence tomography analysis.. *Cardiovascular Diagnosis and Therapy*, **2022**, 12, 77-87	2.6	1
154	Combined Transcatheter Aortic and Mitral Valve Implantation.. *American Journal of Cardiology*, **2022**,	3	
153	Balloon-Expandable Valve for Treatment of Evolut Valve Failure: Implications on Neoskirt Height and Leaflet Overhang.. *JACC: Cardiovascular Interventions*, **2022**, 15, 368-377	5	2
152	Feasibility and Safety of Same-Day Discharge Following Transfemoral Transcatheter Aortic Valve Replacement.. *JACC: Cardiovascular Interventions*, **2022**, 15, 575-589	5	1
151	Impact of Cerebral Embolic Protection Devices on the Incidence and Outcomes of Delirium After Transcatheter Aortic Valve Implantation.. *American Journal of Cardiology*, **2022**,	3	
150	The Spectrum of Valvular Heart Disease and the Importance of "Mild".. *JAMA Network Open*, **2022**, 5, e2211955	10.4	
149	Caval Valve Implantation (CAVI): An Emerging Therapy for Treating Severe Tricuspid Regurgitation. *Journal of Clinical Medicine*, **2021**, 10,	5.1	2
148	Gender Differences in the Outcomes of Transcatheter Mitral Valve Implantation. *American Journal of Cardiology*, **2021**,	3	
147	Impact of baseline conduction abnormalities on outcomes after transcatheter aortic valve replacement with SAPIEN-3. *Catheterization and Cardiovascular Interventions*, **2021**, 98, E127-E138	2.7	2
146	Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial. *Circulation: Cardiovascular Interventions*, **2021**, 14, e010300	6	7
145	Severe Atrial Functional Mitral Regurgitation: Clinical and Echocardiographic Characteristics, Management and Outcomes. *JACC: Cardiovascular Imaging*, **2021**, 14, 797-808	8.4	2
144	Transcatheter Closure of Patent Foramen Ovale: Not Always an "Open or Shut" Case. *Circulation*, **2021**, 143, 1539-1541	16.7	
143	Effect of High-Density Lipoprotein Cholesterol Levels on Overall Survival and Major Adverse Cardiovascular and Cerebrovascular Events. *American Journal of Cardiology*, **2021**, 146, 8-14	3	1

142	Quality Assessment of Published Systematic Reviews in High Impact Cardiology Journals: Revisiting the Evidence Pyramid. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 671569	5.4	1
141	Adverse Events Related to Excimer Laser Coronary Atherectomy: Analysis of the FDA MAUDE Database. *Cardiovascular Revascularization Medicine*, **2021**, 27, 88-89	1.6	0
140	Transcatheter Tricuspid Valve Intervention in Patients With Previous Left Valve Surgery. *Canadian Journal of Cardiology*, **2021**, 37, 1094-1102	3.8	1
139	Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study. *European Heart Journal*, **2021**, 42, 4324-4332	9.5	14
138	COVID-19 May Be Exacerbated by Right-to-Left Interatrial Shunt. *Annals of Thoracic Surgery*, **2021**, 111, 376	2.7	1
137	Excimer Laser Atherectomy in Percutaneous Coronary Intervention: A Contemporary Review. *Cardiovascular Revascularization Medicine*, **2021**, 25, 75-85	1.6	12
136	Oral Calcium Supplements Associate With Serial Coronary Calcification: Insights From Intravascular Ultrasound. *JACC: Cardiovascular Imaging*, **2021**, 14, 259-268	8.4	4
135	Meta-analysis Comparing Outcomes in Patients With and Without Cardiac Injury and Coronavirus Disease 2019 (COVID 19). *American Journal of Cardiology*, **2021**, 141, 140-146	3	12
134	Benefit of Single Antiplatelet Therapy Over Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation. *American Journal of Cardiology*, **2021**, 141, 163-164	3	
133	Coronary artery disease detection using artificial intelligence techniques: A survey of trends, geographical differences and diagnostic features 1991-2020. *Computers in Biology and Medicine*, **2021**, 128, 104095	7	17
132	Outcomes of Mild Aortic Regurgitation After Transcatheter Aortic Valve Replacement. *Structural Heart*, **2021**, 5, 201-207	0.6	0
131	Aspirin Versus Dual Antiplatelet Therapy in Patients Undergoing Trans-Catheter Aortic Valve Implantation, Updated Meta-Analysis. *Cardiovascular Drugs and Therapy*, **2021**, 1	3.9	0
130	Outcomes of transcatheter aortic valve replacement in patients with cognitive dysfunction. *Journal of the American Geriatrics Society*, **2021**, 69, 1363-1369	5.6	0
129	Transcatheter Tricuspid Valve Intervention in Patients With Right Ventricular Dysfunction or Pulmonary Hypertension: Insights From the TriValve Registry. *Circulation: Cardiovascular Interventions*, **2021**, 14, e009685	6	7
128	Roles of Cardiac Computed Tomography in Guiding Transcatheter Tricuspid Valve Interventions. *Current Cardiology Reports*, **2021**, 23, 114	4.2	0
127	Predicting Infective Endocarditis After Transcatheter Aortic Valve Implantation Via a Risk Model. *American Journal of Cardiology*, **2021**, 150, 131-132	3	
126	Predictors of Procedural Success in Patients With Degenerated Surgical Valves Undergoing Transcatheter Aortic Valve-in-Valve Implantation. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 718835	5.4	0
125	Transcatheter Aortic Valve Implantation in Patients With Inflammatory Bowel Disease. *American Journal of Cardiology*, **2021**, 154, 133-135	3	0

124	Outcomes After Transfemoral Transcatheter Aortic Valve Implantation With a SAPIEN 3 Valve in Patients With Cirrhosis of the Liver (a Tertiary Care Center Experience). *American Journal of Cardiology*, **2021**, 160, 75-82	3	0
123	Incidence and Outcomes of Pericardial Effusion and Cardiac Tamponade Following Permanent Pacemaker Implantation After Transcatheter Aortic Valve Implantation. *American Journal of Cardiology*, **2021**, 157, 135-139	3	1
122	Revascularization in the Transcatheter Aortic Valve Replacement Population. *Interventional Cardiology Clinics*, **2021**, 10, 553-563	1.4	
121	Machine learning risk model for predicting in-hospital mortality for patients with infective endocarditis after transcatheter aortic valve replacement. *Cardiovascular Revascularization Medicine*, **2021**,	1.6	1
120	Valve-in-valve transcatheter aortic valve implantation versus repeat surgical aortic valve replacement in patients with a failed aortic bioprosthesis. *EuroIntervention*, **2021**,	3.1	4
119	C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV. *American Journal of Preventive Cardiology*, **2020**, 3, 100091	1.9	0
118	Rethinking the respiratory paradigm of COVID-19: a QholeQ in the argument. *Intensive Care Medicine*, **2020**, 46, 1496-1497	14.5	12
117	Artificial Intelligence in Intracoronary Imaging. *Current Cardiology Reports*, **2020**, 22, 46	4.2	10
116	Outcomes of Transcatheter Aortic Valve Replacement in Transplant Recipients. *Structural Heart*, **2020**, 4, 329-333	0.6	0
115	Statins in a Distorted Mirror of Media. *Current Atherosclerosis Reports*, **2020**, 22, 37	6	11
114	Improving Outcomes With IVUS Guidance During Percutaneous Coronary Interventions. *Current Treatment Options in Cardiovascular Medicine*, **2020**, 22, 1	2.1	1
113	Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial. *JAMA Cardiology*, **2020**, 5, 1136-1143	16.2	23
112	Incidence of Stress Cardiomyopathy During the Coronavirus Disease 2019 Pandemic. *JAMA Network Open*, **2020**, 3, e2014780	10.4	106
111	Conduction disturbances following trancatheter aortic valve implantation: increasing the QpaceQ towards prospective evidence. *European Heart Journal*, **2020**, 41, 2782-2784	9.5	1
110	Outcomes of TTVI in Patients With Pacemaker or Defibrillator Leads: Data From the TriValve Registry. *JACC: Cardiovascular Interventions*, **2020**, 13, 554-564	5	12
109	High-Sensitivity C-Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study. *Journal of the American Heart Association*, **2020**, 9, e013600	6	24
108	Progression of ultrasound plaque attenuation and low echogenicity associates with major adverse cardiovascular events. *European Heart Journal*, **2020**, 41, 2965-2973	9.5	6
107	Corrigendum to: Intraventricular Conduction Disturbances After Transcatheter Aortic Valve Implantation. *Interventional Cardiology Review*, **2020**, 15, e17	4.2	

106	Intraventricular Conduction Disturbances After Transcatheter Aortic Valve Implantation. *Interventional Cardiology Review*, **2020**, 15, e11	4.2	5
105	The importance of detection and percutaneous closure of patent foramen ovale during the coronavirus disease 2019 pandemic. *Kardiologia Polska*, **2020**, 78, 614-617	0.9	3
104	The utilization of single versus double Perclose devices for transfemoral aortic valve replacement access site closure: Insights from Cleveland Clinic Aortic Valve Center. *Catheterization and Cardiovascular Interventions*, **2020**, 96, 442-447	2.7	8
103	An Optimized Approach for Transfemoral Transcatheter Aortic Valve Implantation: A Comprehensive Review and Current Evidence. *Cardiovascular Revascularization Medicine*, **2020**, 21, 1034-1040	1.6	0
102	Recurrent Drug-Eluting Stent In-Stent Restenosis: A State-of-the-Art Review of Pathophysiology, Diagnosis, and Management. *Cardiovascular Revascularization Medicine*, **2020**, 21, 1157-1163	1.6	10
101	Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease. *European Journal of Preventive Cardiology*, **2020**, 27, 1091-1100	3.9	23
100	Weekend Operation and Outcomes of Patients Admitted for Nonelective Coronary Artery Bypass Surgery. *Annals of Thoracic Surgery*, **2020**, 110, 152-157	2.7	4
99	Coronary atherosclerotic plaque progression: contributing factors in statin-treated patients. *Expert Review of Cardiovascular Therapy*, **2020**, 18, 873-880	2.5	1
98	When to use intravascular ultrasound or optical coherence tomography during percutaneous coronary intervention?. *Cardiovascular Diagnosis and Therapy*, **2020**, 10, 1429-1444	2.6	3
97	Atrial Fibrillation in Transthyretin Cardiac Amyloidosis: Predictors, Prevalence, and Efficacy of Rhythm Control Strategies. *JACC: Clinical Electrophysiology*, **2020**, 6, 1118-1127	4.6	19
96	Impact of Massive or Torrential Tricuspid Regurgitation in Patients Undergoing Transcatheter Tricuspid Valve Intervention. *JACC: Cardiovascular Interventions*, **2020**, 13, 1999-2009	5	18
95	Coronary Embolism: A Systematic Review. *Cardiovascular Revascularization Medicine*, **2020**, 21, 367-374	1.6	13
94	Diagnostic Accuracy of 320-Row Computed Tomography for Characterizing Coronary Atherosclerotic Plaques: Comparison with Intravascular Optical Coherence Tomography. *Cardiovascular Revascularization Medicine*, **2020**, 21, 640-646	1.6	3
93	Left main percutaneous coronary intervention-Radial versus femoral access: A systematic analysis. *Catheterization and Cardiovascular Interventions*, **2020**, 95, E201-E213	2.7	5
92	Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study. *European Journal of Preventive Cardiology*, **2020**, 27, 1597-1605	3.9	15
91	The Utility of Rapid Atrial Pacing Immediately Post-TAVR to Predict the Need for Pacemaker Implantation. *JACC: Cardiovascular Interventions*, **2020**, 13, 1046-1054	5	21
90	Woven Coronary Disease: Friend or Foe?. *Circulation: Cardiovascular Interventions*, **2019**, 12, e008087	6	1
89	Aortic distensibility is associated with both resting and hyperemic coronary blood flow. *American Journal of Physiology - Heart and Circulatory Physiology*, **2019**, 317, H811-H819	5.2	7

88	Trends in the Use of Short-Term Mechanical Circulatory Support in the United States An Analysis of the 2012 2015 National Inpatient Sample. *Structural Heart*, **2019**, 3, 499-506	0.6	4
87	Meta-Analysis Comparing Outcomes in Patients Undergoing Transcatheter Aortic Valve Implantation With Versus Without Percutaneous Coronary Intervention. *American Journal of Cardiology*, **2019**, 124, 1757-1764	3	13
86	LDL-C Targets in Secondary Prevention: How Low Should We Go?. *Current Cardiovascular Risk Reports*, **2019**, 13, 1	0.9	4
85	Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial. *JAMA Cardiology*, **2019**, 4, 314-320	16.2	44
84	Visit-to-Visit Blood Pressure Variability, Coronary Atheroma Progression, and Clinical Outcomes. *JAMA Cardiology*, **2019**, 4, 437-443	16.2	38
83	Long-Term Outcomes of the FORMA Transcatheter Tricuspid Valve Repair System for the Treatment of Severe Tricuspid Regurgitation: Insights From the First-in-Human Experience. *JACC: Cardiovascular Interventions*, **2019**, 12, 1438-1447	5	21
82	Blood Pressure Variability and Arterial Stiffness-Chicken or Egg?-Reply. *JAMA Cardiology*, **2019**, 4, 1050-1051	16.2	
81	Unilateral Access Is Safe and Facilitates Peripheral Bailout During Transfemoral-Approach Transcatheter Aortic Valve Replacement. *JACC: Cardiovascular Interventions*, **2019**, 12, 2210-2220	5	10
80	Transcatheter aortic valve replacement: relative safety and efficacy of the procedure with different devices. *Expert Review of Medical Devices*, **2019**, 16, 11-24	3.5	10
79	Blood Disorders in Patients Undergoing Transcatheter Aortic Valve Replacement: A Review. *JACC: Cardiovascular Interventions*, **2019**, 12, 1-11	5	17
78	The Portico transcatheter aortic valve for the treatment of severe aortic stenosis. *Future Cardiology* , **2019**, 15, 31-37	1.3	1
77	Visit-to-visit cholesterol variability correlates with coronary atheroma progression and clinical outcomes. *European Heart Journal*, **2018**, 39, 2551-2558	9.5	40
76	Subclinical Leaflet Thrombosis and Clinical Outcomes after TAVR: A Systematic Review and Meta-Analysis. *Structural Heart*, **2018**, 2, 223-228	0.6	7
75	Concomitant or Staged Transcatheter Treatment for Severe Combined Aortic and Mitral Valve Disease. *Revista Espanola De Cardiologia (English Ed)*, **2018**, 71, 676-679	0.7	1
74	Warfarin Use Is Associated With Progressive Coronary Arterial Calcification: Insights From Serial Intravascular Ultrasound. *JACC: Cardiovascular Imaging*, **2018**, 11, 1315-1323	8.4	34
73	Three- and 6-month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite drug-eluting stent: The ANCHOR study. *Catheterization and Cardiovascular Interventions*, **2018**, 91, 435-443	2.7	5
72	Future of transcatheter aortic valve implantation - evolving clinical indications. *Nature Reviews Cardiology*, **2018**, 15, 57-65	14.8	47
71	Transcatheter Treatment of Bicuspid Aortic Valve Disease: Imaging and Interventional Considerations. *Frontiers in Cardiovascular Medicine*, **2018**, 5, 91	5.4	11

70	Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases. *Clinical Pharmacology and Therapeutics*, **2018**, 104, 257-268	6.1	8
69	Coronary arterial calcification: A review of mechanisms, promoters and imaging. *Trends in Cardiovascular Medicine*, **2018**, 28, 491-501	6.9	34
68	Transcatheter Tricuspid Valve Interventions: Landscape, Challenges, and Future Directions. *Journal of the American College of Cardiology*, **2018**, 71, 2935-2956	15.1	149
67	Transcarotid Compared With Other Alternative Access Routes for Transcatheter Aortic Valve Replacement. *Circulation: Cardiovascular Interventions*, **2018**, 11, e006388	6	49
66	High-Density Lipoprotein-Targeted Therapies-Not Dead Yet-Reply. *JAMA Cardiology*, **2018**, 3, 1255-1256	16.2	1
65	Feasibility, safety, and efficacy of transcatheter aortic valve replacement without balloon predilation: A systematic review and meta-analysis. *Catheterization and Cardiovascular Interventions*, **2017**, 90, 839-850	2.7	29
64	Bioprosthetic Valve Thrombosis. *Journal of the American College of Cardiology*, **2017**, 69, 2193-2211	15.1	96
63	Changes in Coagulation and Platelet Activation Markers Following Transcatheter Left Atrial Appendage Closure. *American Journal of Cardiology*, **2017**, 120, 87-91	3	13
62	Predictors and Association With Clinical Outcomes of the Changes in Exercise Capacity After Transcatheter Aortic Valve Replacement. *Circulation*, **2017**, 136, 632-643	16.7	36
61	Prosthetic Mitral Surgical Valve in Transcatheter Aortic Valve Replacement Recipients: A Multicenter Analysis. *JACC: Cardiovascular Interventions*, **2017**, 10, 1973-1981	5	17
60	Regression of coronary atherosclerosis with infusions of the high-density lipoprotein mimetic CER-001 in patients with more extensive plaque burden. *Cardiovascular Diagnosis and Therapy*, **2017**, 7, 252-263	2.6	32
59	Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Lower-Surgical-Risk Patients With Chronic Obstructive Pulmonary Disease. *American Journal of Cardiology*, **2017**, 120, 1863-1868	3	9
58	Conduction Disturbances After Transcatheter Aortic Valve Replacement: Current Status and Future Perspectives. *Circulation*, **2017**, 136, 1049-1069	16.7	231
57	Transcatheter Tricuspid Valve Repair With a New Transcatheter Coaptation System for the Treatment of Severe Tricuspid Regurgitation: 1-Year Clinical and Echocardiographic Results. *JACC: Cardiovascular Interventions*, **2017**, 10, 1994-2003	5	71
56	Aortic Bioprosthetic Valve Durability: Incidence, Mechanisms, Predictors, and Management of Surgical and Transcatheter Valve Degeneration. *Journal of the American College of Cardiology*, **2017**, 70, 1013-1028	15.1	159
55	Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN. *Atherosclerosis*, **2017**, 263, 137-144	3.1	29
54	Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. *American Journal of Cardiovascular Drugs*, **2016**, 16, 55-65	4	67
53	The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events. *European Journal of Preventive Cardiology*, **2016**, 23, 474-85	3.9	8

52	Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2016**, 36, 2220-2228	9.4	86
51	Warfarin and Antiplatelet Therapy Versus Warfarin Alone for Treating Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement. *JACC: Cardiovascular Interventions* , **2016**, 9, 1706-17	5	89
50	Sex Differences in Nonculprit Coronary Plaque Microstructures on Frequency-Domain Optical Coherence Tomography in Acute Coronary Syndromes and Stable Coronary Artery Disease. *Circulation: Cardiovascular Imaging*, **2016**, 9,	3.9	35
49	Coronary atheroma progression rates in men and women following high-intensity statin therapy: A pooled analysis of REVERSAL, ASTEROID and SATURN. *Atherosclerosis*, **2016**, 254, 78-84	3.1	16
48	Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2016**, 316, 2373-2384	27.4	549
47	Self-expanding Portico Valve Versus Balloon-expandable SAPIEN XT Valve in Patients With Small Aortic Annuli: Comparison of Hemodynamic Performance. *Revista Espanola De Cardiologia (English Ed)*, **2016**, 69, 501-8	0.7	4
46	TAVI or No TAVI: identifying patients unlikely to benefit from transcatheter aortic valve implantation. *European Heart Journal*, **2016**, 37, 2217-25	9.5	115
45	Confirmation of the Intracoronary Near-Infrared Spectroscopy Threshold of Lipid-Rich Plaques That Underlie ST-Segment-Elevation Myocardial Infarction. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2016**, 36, 1010-5	9.4	35
44	"Buddy wire" technique in transcatheter aortic valve implantation with a balloon-expandable valve: A rescue option in the setting of direct valve implantation (without predilation). *Archivos De Cardiologia De Mexico*, **2016**, 86, 180-2	0.2	2
43	Therapeutic modulation of the natural history of coronary atherosclerosis: lessons learned from serial imaging studies. *Cardiovascular Diagnosis and Therapy*, **2016**, 6, 282-303	2.6	10
42	Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events. *American Journal of Cardiology*, **2016**, 118, 647-55	3	17
41	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). *American Heart Journal*, **2016**, 176, 83-92	4.9	32
40	Impact of New-Onset Left Bundle Branch Block and Periprocedural Permanent Pacemaker Implantation on Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-Analysis. *Circulation: Cardiovascular Interventions*, **2016**, 9, e003635	6	152
39	Comparing Coronary Atheroma Progression Rates and Coronary Events in the United States, Canada, Latin America, and Europe. *American Journal of Cardiology*, **2016**, 118, 1616-1623	3	1
38	Response to Comment on Stegman et al. High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care 2014;37:3114-3120. *Diabetes Care*, **2015**, 38, e28-9	14.6	1
37	Impact of statins on serial coronary calcification during atheroma progression and regression. *Journal of the American College of Cardiology*, **2015**, 65, 1273-1282	15.1	319
36	Effects of aliskiren in diabetic and non-diabetic patients with coronary artery disease: Insights from AQUARIUS. *Atherosclerosis*, **2015**, 243, 553-9	3.1	3
35	Plaque vulnerability at non-culprit lesions in obese patients with coronary artery disease: Frequency-domain optical coherence tomography analysis. *European Journal of Preventive Cardiology*, **2015**, 22, 1331-9	3.9	6

34	Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. *Atherosclerosis*, **2015**, 242, 490-5	3.1	28
33	Near-Infrared Spectroscopy Enhances Intravascular Ultrasound Assessment of Vulnerable Coronary Plaque: A Combined Pathological and In Vivo Study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 2423-31	9.4	39
32	Coronary atheroma composition and its association with segmental endothelial dysfunction in non-ST segment elevation myocardial infarction: novel insights with radiofrequency (iMAP) intravascular ultrasonography. *International Journal of Cardiovascular Imaging*, **2015**, 31, 247-57	2.5	4
31	Statin-induced coronary artery disease regression rates differ in men and women. *Current Opinion in Lipidology*, **2015**, 26, 276-81	4.4	11
30	Atheroma progression in hyporesponders to statin therapy. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 990-5	9.4	49
29	Inflammation, plaque progression and vulnerability: evidence from intravascular ultrasound imaging. *Cardiovascular Diagnosis and Therapy*, **2015**, 5, 280-9	2.6	15
28	Coronary artery wall shear stress is associated with endothelial dysfunction and expansive arterial remodelling in patients with coronary artery disease. *EuroIntervention*, **2015**, 10, 1440-8	3.1	20
27	High-risk coronary atheroma: the interplay between ischemia, plaque burden, and disease progression. *Journal of the American College of Cardiology*, **2014**, 63, 1134-1140	15.1	27
26	Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. *European Heart Journal Cardiovascular Imaging*, **2014**, 15, 380-8	4.1	111
25	Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy. *American Journal of Cardiology*, **2014**, 114, 1465-72	3	37
24	High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. *Diabetes Care*, **2014**, 37, 3114-20	14.6	45
23	Sex-related differences of coronary atherosclerosis regression following maximally intensive statin therapy: insights from SATURN. *JACC: Cardiovascular Imaging*, **2014**, 7, 1013-22	8.4	40
22	Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2014**, 34, 2465-72	9.4	33
21	Progression of coronary atherosclerosis in stable patients with ultrasonic features of high-risk plaques. *European Heart Journal Cardiovascular Imaging*, **2014**, 15, 1035-41	4.1	16
20	Myeloperoxidase levels predict accelerated progression of coronary atherosclerosis in diabetic patients: insights from intravascular ultrasound. *Atherosclerosis*, **2014**, 232, 377-83	3.1	37
19	The impact of lumen size and microvascular resistance on Fourier-domain optical coherence tomography (FD-OCT) coronary measurements. *International Journal of Cardiology*, **2014**, 174, 210-1	3.2	1
18	Frequency-domain optical coherence tomographic analysis of plaque microstructures at nonculprit narrowings in patients receiving potent statin therapy. *American Journal of Cardiology*, **2014**, 114, 549-54	3	25
17	Left main coronary arterial endothelial function and heterogenous segmental epicardial vasomotor reactivity in vivo: novel insights with intravascular ultrasonography. *European Heart Journal Cardiovascular Imaging*, **2014**, 15, 1270-80	4.1	0

16	Spotty calcification and plaque vulnerability in vivo: frequency-domain optical coherence tomography analysis. *Cardiovascular Diagnosis and Therapy*, **2014**, 4, 460-9	2.6	51
15	Left main coronary atherosclerosis progression, constrictive remodeling, and clinical events. *JACC: Cardiovascular Interventions*, **2013**, 6, 29-35	5	29
14	Lipidomics: Opportunities to Identify New Causal Mechanisms and Therapeutics for Atherosclerosis. *Current Cardiovascular Risk Reports*, **2013**, 7, 60-65	0.9	
13	Exploring coronary atherosclerosis with intravascular imaging. *International Journal of Cardiology*, **2013**, 168, 670-9	3.2	38
12	Factors underlying regression of coronary atheroma with potent statin therapy. *European Heart Journal*, **2013**, 34, 1818-25	9.5	49
11	Coronary endothelium-dependent vasoreactivity and atheroma volume in subjects with stable, minimal angiographic disease versus non-ST-segment-elevation myocardial infarction: an intravascular ultrasound study. *Circulation: Cardiovascular Imaging*, **2013**, 6, 674-82	3.9	7
10	Coronary atheroma volume and cardiovascular events during maximally intensive statin therapy. *European Heart Journal*, **2013**, 34, 3182-90	9.5	69
9	C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. *Circulation* , **2013**, 128, 2395-403	16.7	88
8	The complementary roles of imaging and ‘omics’ for future anti-atherosclerotic drug development. *Current Pharmaceutical Design*, **2013**, 19, 5963-71	3.3	2
7	Optimizing outcomes during left main percutaneous coronary intervention with intravascular ultrasound and fractional flow reserve: the current state of evidence. *JACC: Cardiovascular Interventions*, **2012**, 5, 697-707	5	53
6	Intracoronary ECG ST-segment recovery during primary percutaneous intervention for ST-segment myocardial infarction: insights from a cardiac MRI study. *Catheterization and Cardiovascular Interventions*, **2012**, 80, 746-53	2.7	4
5	The distinctive nature of atherosclerotic vascular disease in diabetes: pathophysiological and morphological insights. *Current Diabetes Reports*, **2012**, 12, 280-5	5.6	16
4	Coronary β2-adrenoreceptors mediate endothelium-dependent vasoreactivity in humans: novel insights from an in vivo intravascular ultrasound study. *European Heart Journal*, **2012**, 33, 495-504	9.5	33
3	Treating stable ischemic heart disease with percutaneous coronary intervention - The debate continues. *Cardiovascular Diagnosis and Therapy*, **2012**, 2, 264-7	2.6	2
2	Intravascular imaging of vulnerable coronary plaque: current and future concepts. *Nature Reviews Cardiology*, **2011**, 8, 131-9	14.8	68
1	What Is the Role of Cardiac Magnetic Resonance Imaging in Transcatheter Management of Aortic Valve Stenosis?. *Structural Heart*,1-13	0.6	